Highlights

  • Searches were conducted at 11 places
  • The two arrested are S Eswara Reddy, Joint Drug Controller (India), CDSCO and Dinesh Dua, Director Synergy Network India Private Limited.

Latest news

iQOO Buds Review: Monster Battery and Serious Gaming Chops for under ₹2,000 

iQOO Buds Review: Monster Battery and Serious Gaming Chops for under ₹2,000 

Repo rate today at 5.25%: how long an RBI decision takes to reach your home loan interest rate

Repo rate today at 5.25%: how long an RBI decision takes to reach your home loan interest rate

CMF Buds Neo Review: 35dB ANC, 52-Hour Battery and Incredible Value

CMF Buds Neo Review: 35dB ANC, 52-Hour Battery and Incredible Value

iQOO Z11 Review: A Balanced Mid-Range Powerhouse

iQOO Z11 Review: A Balanced Mid-Range Powerhouse

Samsung Galaxy Watch 9 Review: Familiar, Faster And Better Where It Matters

Samsung Galaxy Watch 9 Review: Familiar, Faster And Better Where It Matters

Samsung Galaxy Watch Ultra2 Review: A Smarter, Tougher and Longer-Lasting Ultra

Samsung Galaxy Watch Ultra2 Review: A Smarter, Tougher and Longer-Lasting Ultra

Gabit Smart Ring Review: A Better Way To Track Your Health? 

Gabit Smart Ring Review: A Better Way To Track Your Health? 

Xiaomi Power Bank 5i 20000 67W Review: A Powerful Travel Companion

Xiaomi Power Bank 5i 20000 67W Review: A Powerful Travel Companion

Bribe allegations on Biocon's injection unit, Joint drugs controller arrested

A total of six accused have been booked by the CBI including “unknown officials of CDSCO”

 Bribe allegations on Biocon's injection unit, Joint drugs controller arrested

Alleging charges of bribe in a case involving a unit of Kiran Mazumdar-Shaw backed Bicon, the Central Bureau of Investigation has arrested a Joint Drug Controller (JDC) and also a Director of Synergy Network India.

As per reports, the agency laid a trap wherein the JDC of CDSCO was caught while accepting a bribe of Rs 4 lakh from the Director of Synergy Network India Private Limited. The said Director was also caught.

The bribe reportedly was to clear Biocon unit's injection by waiving phase-three clinical trial of Insulin Aspart injection, an underdevelopment product of Biocon Biologics.

Also read/watch| No wrong doing! Kiran Mazumdar-Shaw lashes out, waiver was procedural

"Phase 3 clinical trial is an important regulatory mechanism to assess the safety of a pharma product. Any attempt to waive them off can have serious public health safety repercussions," an official said

Searches were conducted at 11 places located at Delhi, Noida, Gurugram, Patna and Bengaluru. The agency claims to have recovered alleged incriminating documents/articles.

Denying allegations of any wrongdoing, a spokesperson for Biocon Biologics said "All our product approvals are legitimate and backed by science and clinical data. Our bAspart is approved in Europe and many other countries. We follow the due regulatory process for all our product approvals by DCGI. The entire application process in India is online and all meeting minutes are in the public domain. We are co-operating with the investigation agency." - With Inputs from PTI & ET

Frequently Asked Questions

A Joint Drug Controller (JDC) of the CDSCO and a Director of Synergy Network India Private Limited were arrested.

ADVERTISEMENT

Up Next

 Bribe allegations on Biocon's injection unit, Joint drugs controller arrested

Bribe allegations on Biocon's injection unit, Joint drugs controller arrested

Repo rate today at 5.25%: how long an RBI decision takes to reach your home loan interest rate

Repo rate today at 5.25%: how long an RBI decision takes to reach your home loan interest rate

Step-by-step guide to apply for a mortgage loan online with minimal documentation

Step-by-step guide to apply for a mortgage loan online with minimal documentation

Honda Activa 6G: Everything You Need to Know Before Buying

Honda Activa 6G: Everything You Need to Know Before Buying

How much does a ULIP plan really cost? A break-down of all charges

How much does a ULIP plan really cost? A break-down of all charges

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

ADVERTISEMENT

editorji-whatsApp

More videos

Reliance denies buying Iranian oil amid US sanctions waiver

Reliance denies buying Iranian oil amid US sanctions waiver

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

Govt announces seven measures to help boost exports

Govt announces seven measures to help boost exports

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI pauses rate cuts, retains interest rate at 5.25 pc

RBI pauses rate cuts, retains interest rate at 5.25 pc

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

Editorji Technologies Pvt. Ltd. © 2022 All Rights Reserved.